Related Experiment Video
Updated: Jul 13, 2026
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Ytterbium-169: a promising new radionuclide for intravascular brachytherapy
N S Patel1, P Fan, S T Chiu-Tsao
1Department of Radiation Oncology, Beth Israel Medical Center and St. Luke's-Roosevelt Hospital Center, 10 Union Square East, New York, NY 10003, USA.
Purpose:
To explore the feasibility of 169Yb (gamma, 93 keV) as a new radionuclide for intravascular brachytherapy (IVBT) in terms of dose distribution, penetration power, and radiation safety features as compared with 125I and 192Ir.
Methods:
The dose distributions for catheter-based sources, 169Yb, 125I, and 192Ir, in homogeneous water and in the presence of calcium and a steel stent have been determined and compared using the Monte Carlo method (MCNP4B2 code). The dose rates of the sources were evaluated from 0.02 to 100 cm.
Results:
In the short distance range (0.02
Conclusion:
169Yb is a promising new radionuclide for IVBT. It has a much better penetrating power through calcified plaques and stents compared with the low-energy source 125I. It also provides easier radiation protection measures for cardiac cathlab personnel than the high-energy source 192Ir, while preserving a favorable dose distribution in tissues surrounding an arterial vessel.
